trimethobenzamide hydrochloride

trimethobenzamide hydrochloride

[trīmeth′ōben′zəmīd]
an anticholinergic and antiemetic.
indications It is prescribed for the relief of postoperative nausea and vomiting and nausea and vomiting associated with gastroenteritis.
contraindications Reye's syndrome or known hypersensitivity to benzocaine-like local anesthetic or this drug prohibits its use.
adverse effects Among the most serious adverse effects with high doses are drowsiness, allergic reactions, and extrapyramidal reactions. Adverse reactions are rare at usual dosages.
References in periodicals archive ?
Tigan and other suppository drug products that contain trimethobenzamide hydrochloride have not been shown to be effective for nausea and vomiting and should no longer be marketed, according to the Food and Drug Administration.
King Pharmaceuticals' Tigan(R) is Sole FDA-approved Trimethobenzamide Hydrochloride Capsule in U.
Food and Drug Administration's ("FDA") publication of a Federal Register notice declaring the continued marketing of unapproved trimethobenzamide hydrochloride capsule products unlawful and subject to FDA regulatory action.
FDA shall publish an appropriate notice in the Federal Register stating, among other things, that any trimethobenzamide hydrochloride drug product marketed without an application approved under section 505 of the Federal Food, Drug, and Cosmetic Act is subject to FDA regulatory action.
Food and Drug Administration (FDA) approved the new drug application (NDA) for Tigan(R) 300mg capsules on December 13, 2001, making the product the only FDA approved trimethobenzamide hydrochloride capsule in the United States.
Gregory commented further stating, "As the only trimethobenzamide hydrochloride capsule proven safe and effective, we are working diligently to protect the long-term growth potential of this product.
This release contains forward-looking statements which reflect management's current views of future events and operations, including, but not limited to, statements pertaining to the agreement of the FDA to publish an appropriate notice in the Federal Register stating, among other things, that any trimethobenzamide hydrochloride drug product marketed without an application approved under section 505 of the Federal Food, Drug, and Cosmetic Act is subject to FDA regulatory action; the continued successful execution of the Company's growth strategies, and potential patent protection for Tigan(R) 300mg capsules.
As a result, King now has the only FDA approved trimethobenzamide hydrochloride capsule in the United States.